View Older Stories View More Recent Stories
-
Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference
-
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
-
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
-
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) Announces FDA Acceptance of BLA of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent C
-
Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program
-
Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (A
-
Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022
-
Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022
-
Citius Pharmaceuticals (CTXR) Submits BLA to FDA for Denileukin Diftitox
-
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous
-
Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Meta
-
Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute
-
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals (CTXR) Reiterated at Buy by Dawson James on I/ONTAK Spinoff, $10 Price Target Maintained
-
Citius Pharmaceuticals (CTXR) to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company
-
Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company
-
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
-
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
-
Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
-
Citius Pharmaceuticals (CTXR) Provides Business Update, Highlights Upcoming Milestones
-
Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones
-
Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
-
Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022
-
Citius Pharmaceuticals (CTXR) Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates
-
Citius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates
-
Citius Pharmaceuticals (CTXR) Reports Topline Data from Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK for Treatment of CTCL in Support of BLA Submission
-
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Supp
-
Citius Pharmaceuticals, Inc. to Present at Upcoming March 2022 Conferences
-
Citius Pharmaceuticals (CTXR) Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido
-
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
-
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business Update
-
Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences
-
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update
-
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls
-
Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients
-
Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777)
-
Citius Pharmaceuticals to Present at Upcoming October Investor Conferences
-
Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021
-
Citius Pharmaceuticals (CTXR) PT Raised to $10 at Dawson James
-
Citius Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
-
Citius Pharmaceuticals (CTXR) Acquires Dr. Reddy's (RDY) Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indicatio
-
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
